Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Reata Pharma (NQ: RETA )

48.87 -0.63 (-1.27%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 893,271
Open 48.89
Bid (Size) 46.03 (1)
Ask (Size) 51.12 (1)
Prev. Close 49.50
Today's Range 48.24 - 50.99
52wk Range 18.47 - 50.99
Shares Outstanding 36,536,919
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The Nasdaq Is Rebounding: 2 Supercharged Growth Stocks to Buy in February
These two growth stocks might deliver enormous gains for shareholders this month. 
Via The Motley Fool
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga

Performance

YTD
+33.12%
+33.12%
1 Month
+41.20%
+41.20%
3 Month
+40.03%
+40.03%
6 Month
+103.12%
+103.12%
1 Year
+84.83%
+84.83%

More News

Read More
Looking Into Reata Pharmaceuticals's Return On Capital Employed
Via Benzinga
Reata Pharmaceuticals To Jump 220%? Plus JP Morgan Predicts $51 For Las Vegas Sands
Via Benzinga
Analyst Ratings for Reata Pharmaceuticals
Via Benzinga
Why Reata Pharmaceuticals Stock Is Soaring Today
Via The Motley Fool
Reata Pharmaceuticals Announces Participation in the Guggenheim 2022 Immunology and Neurology Conference and the Stifel 2022 Healthcare Conference
From Reata Pharmaceuticals, Inc.
Via Business Wire
Planet Fitness To Surge Over 25%? Plus Morgan Stanley Cuts PT On This Stock By 50%
Via Benzinga
DuPont, Expeditors International, Planet Fitness And Other Big Gainers From Tuesday
Via Benzinga
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Via Benzinga
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Reata Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
From Reata Pharmaceuticals, Inc.
Via Business Wire
Reata Pharmaceuticals, Inc. to Report Third Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on November 8, 2022
From Reata Pharmaceuticals, Inc.
Via Business Wire
2 On-Fire Biotech Stocks That Are Crushing the Bear Market
Via The Motley Fool
Reata Pharmaceuticals Announces Presentations at the International Congress for Ataxia Research 2022
From Reata Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2022
Via Benzinga
Why Minerva Neurosciences Shares Dipped By Around 70%; Here Are 90 Biggest Movers From Yesterday
Via Benzinga
Why Laser Photonics Shares Surged By Around 19%; Here Are 70 Biggest Movers From Friday
Via Benzinga
Dow Dips 375 Points; S&P 500 Down Over 2%
Via Benzinga
Why Is Reata Pharmaceuticals (RETA) Stock Up 15% Today?
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Morgan Stanley Shares Are Trading Lower, Here Are 43 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Nasdaq Tumbles Over 200 Points; Crude Oil Falls Sharply
Via Benzinga
US Stocks Open Lower; Dow Drops Over 100 Points
Via Benzinga
Reata Pharmaceuticals Announces that the FDA Does Not Plan to Hold an Advisory Committee Meeting to Discuss the NDA for Omaveloxolone for Friedreich’s Ataxia
From Reata Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.